(182 days)
The Aqua Medical RF Vapor System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to the esophagus.
Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, Angiodysplasia, Gastric Antral Vascular Ectasia (GAVE) and Radiation Proctitis (RP). The device is to be used in adults only.
The Aqua RF Vapor System uses a catheter to deliver heat to the tissue surface undergoing treatment. The heat, which is created by the application of RF energy to a bipolar electrode pair located inside the catheter tip, is delivered to the tissue through heated water vapor generated inside the catheter. Application of heat to the tissue results in coagulation of the tissues being treated. This technique avoids the need for direct RF energy application to heat the tissue.
The Aqua Medical RF Vapor System consists of the following components:
- Aqua RF Vapor Generator: A software-controlled RF generator is operated through a graphical user interface (GUI) and incorporates a syringe pump that delivers saline to the catheter. Delivery of bipolar RF energy to the catheter is controlled either by an accessory foot pedal or a button incorporated in the disposable catheter.
- Aqua RF Vapor Catheter: a disposable, sterile, single-use catheter with a diameter of 7 F (2.3 mm) and a length of 145 cm. It includes an integrated cable for attachment to the generator and a Luer-connector that facilitates connection to the saline delivery tubing.
- Saline Delivery Tubing and Syringe: Tubing and syringe (60cc) that provide a means of delivering saline to the catheter during treatment.
The Aqua Medical RF Vapor System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract, including the esophagus. This covers conditions such as Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, Angiodysplasia, Gastric Antral Vascular Ectasia (GAVE), and Radiation Proctitis (RP) in adults. The device was deemed substantially equivalent to its predicate, the Halo 90 System by Barrx Medical, Inc.
Here's an analysis of the acceptance criteria and study findings based on the provided text:
Acceptance Criteria and Reported Device Performance
The document does not explicitly state quantitative acceptance criteria or precise reported device performance metrics in a readily tables format as might be expected for a diagnostic AI device. Instead, the "acceptance criteria" appear to be demonstrating substantial equivalence to the predicate device, the HALO® System, through comparative testing. The performance is assessed in terms of its ability to achieve similar tissue coagulation effects.
| Acceptance Criterion (Implicit) | Reported Device Performance |
|---|---|
| Biocompatibility | All tests successfully conducted: Cytotoxicity, Hemolysis, Systemic Toxicity, Intracutaneous, Sensitization, Pyrogenicity. |
| Electrical Safety and EMC | Complied with IEC 60601-1:2005/EN 60601-1:2006 and IEC 60601-1-2:2007 standards. |
| Software V&V | Verification and validation testing conducted, documentation provided, considered "major" level of concern. |
| Bench Testing | HW Verification Testing, System Validation Testing, Distal Assembly Pull Test, Lesion Comparative testing successfully completed. |
| Animal Study (Tissue Coagulation Ability) | Demonstrated ability to create thermal coagulative tissue injury that penetrates in depth to the external muscularis of the esophagus in healthy swine. No pathological complications, esophageal perforation, significant hemorrhage, or clinical complications. Results showed substantial equivalence to HALO® system. |
| Substantial Equivalence to Predicate | The Aqua Medical RF Vapor System has the same indications for use and is substantially equivalent in technological and performance characteristics to the HALO® predicate. |
2. Sample Size Used for the Test Set and Data Provenance
The "test set" in this context refers to the animal study conducted to demonstrate the therapeutic effect.
- Sample Size: A total of 6 animals (swine) were utilized in the animal study.
- 3 animals were treated and evaluated acutely (Day = 0).
- 3 animals were treated and evaluated subacutely (48 hours).
- Data Provenance: The study was conducted on healthy swine, suggesting a controlled, prospective animal study environment. The country of origin is not specified, but it's an industry-conducted study for regulatory submission.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The document states, "The histopathological evaluation assessed acute thermal coagulation through the cross-sectional layers of the esophagus."
- Number of Experts: Not explicitly stated.
- Qualifications of Experts: The text mentions "histopathological evaluation," which implies assessment by qualified pathologists. However, specific qualifications (e.g., years of experience, board certification) are not provided.
4. Adjudication Method for the Test Set
The document does not describe an explicit adjudication method for the histopathological evaluation. It states that the evaluation was conducted, but details on how agreement was reached among multiple potential evaluators (if more than one was involved) are absent. It's common for a single expert or a small group to provide the assessment in such studies without a formal adjudication process beyond standard peer review.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
- No, an MRMC comparative effectiveness study was not done.
- The device is a direct therapeutic device (RF vapor system for tissue coagulation), not a diagnostic AI device intended to assist human readers in image interpretation. Therefore, the concept of "human readers improve with AI vs without AI assistance" is not applicable to this type of medical device submission.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
- This question is not applicable in the context of the Aqua Medical RF Vapor System. This is a therapeutic device that physically treats tissue, not an AI algorithm. Its operation involves user interaction (choice of power settings, advancing the catheter), making "standalone algorithm performance" an irrelevant concept here.
7. The Type of Ground Truth Used (Expert Consensus, Pathology, Outcomes Data, etc.)
The ground truth for evaluating the device's performance in the animal study was based on histopathological evaluation. This involved assessing "acute thermal coagulation through the cross-sectional layers of the esophagus."
8. The Sample Size for the Training Set
- Not applicable. This device is a hardware and software system for therapy delivery, not an AI/machine learning model that undergoes a "training phase" on a dataset in the conventional sense. The software primarily controls the RF generator and syringe pump based on user input and predefined parameters.
9. How the Ground Truth for the Training Set Was Established
- Not applicable, as there is no "training set" in the context of an AI/ML model for this device. The software verification and validation would have been performed against functional requirements and design specifications rather than against a ground truth dataset from a training set.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
June 21, 2019
Aqua Medical, Inc. % Bosmat Friedman Regulatory Affairs Consultant ProMedoss, Inc. 3521 Hatwynn Road Charlotte, NC 28269
Re: K183595
Trade/Device Name: Aqua Medical RF Vapor System Regulation Number: 21 CFR§ 876.4300 Regulation Name: Endoscopic Electrosurgical Unit and Accessories Regulatory Class: II Product Code: KNS, GEI Dated: May 17, 2019 Received: May 20, 2019
Dear Bosmat Friedman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
{1}------------------------------------------------
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatoryinformation/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Shanil P. Haugen, Ph.D. Acting Assistant Division Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of Gastrorenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K183595
Device Name Aqua Medical RF Vapor System
The Aqua Medical RF Vapor System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to the esophagus.
Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, Angiodysplasia, Gastric Antral Vascular Ectasia (GAVE) and Radiation Proctitis (RP). The device is to be used in adults only.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW!"
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.
{3}------------------------------------------------
510(K) SUMMARY [as required by section 807.92(c)] Aqua Medical RF Vapor System 510(k) Number K183595
1. SUBMITTER
Applicant's Name:
Aqua Medical, Inc. 191 West Second St. Santa Ana, CA 92701 Phone: 949-233-5172
Contact Person:
Bosmat Friedman Regulatory Affairs Consultant 3521 Hatwynn Rd. Charlotte, NC 28269 Phone: 647-975-3974 bosmat.f@promedoss.com
Date Prepared:
June 20, 2019
2. DEVICE
Trade Name: Aqua Medical RF Vapor System
Classification Name: Endoscopic electrosurgical unit and accessories Product Code: KNS Regulation No: 876.4300 Class: 2 Review Panel: Gastroenterology/Urology
Classification Name: Electrosurgical cutting and coagulation device and accessories Product Code: GEI Regulation No: 878.4400 Class: 2 Review Panel: General & Plastic Surgery
3. PREDICATE DEVICE
Primary predicate:
4. DEVICE DESCRIPTION
The Aqua RF Vapor System uses a catheter to deliver heat to the tissue surface undergoing treatment. The heat, which is created by the application of RF energy
{4}------------------------------------------------
to a bipolar electrode pair located inside the catheter tip, is delivered to the tissue through heated water vapor generated inside the catheter. Application of heat to the tissue results in coagulation of the tissues being treated. This technique avoids the need for direct RF energy application to heat the tissue.
The Aqua Medical RF Vapor System consists of the following components:
- Aqua RF Vapor Generator: A software-controlled RF generator is operated through a graphical user interface (GUI) and incorporates a syringe pump that delivers saline to the catheter. Delivery of bipolar RF energy to the catheter is controlled either by an accessory foot pedal or a button incorporated in the disposable catheter.
- -Aqua RF Vapor Catheter: a disposable, sterile, single-use catheter with a diameter of 7 F (2.3 mm) and a length of 145 cm. It includes an integrated cable for attachment to the generator and a Luer-connector that facilitates connection to the saline delivery tubing.
- -Saline Delivery Tubing and Syringe: Tubing and syringe (60cc) that provide a means of delivering saline to the catheter during treatment.
Mode of Operation
Access to the target tissue is gained using standard endoscopic techniques. An endoscope with the FDA cleared Olympus endoscope distal attachment cap is advanced to the treatment location. The treatment catheter is inserted through the working channel of the endoscope with a minimum of a 2.8 mm working channel, and advanced to the distal end of the endoscope until the distal tip is completely visible. The endoscope and catheter are advanced to the treatment site and the target tissue is engaged with the endoscopic cap. Bipolar RF energy is then delivered to the bipolar electrode pair in the catheter, while saline is flowing through the catheter lumen and generates heated water vapor to treat the targeted tissue.
The user chooses the power via the generator's touch-screen interface. The generator creates heated water vapor by delivering a constant bipolar RF output to the bipolar electrode contained within the lumen of the disposable catheter. The software commands the integrated syringe pump to dispense saline at a flow rate proportional to the user selected power setting. Heated water vapor, generated as saline flows over the energized electrode, is delivered to the tissue through the distal tip of the catheter. The time of application of heated water vapor determines the depth of treatment.
5. INDICATIONS FOR USE
The Aqua Medical RF Vapor System is indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including but not limited to the esophagus.
Indications include Esophageal Ulcers, Mallory-Weiss tears, Arteriovenous Malformations, Angiomata, Barrett's Esophagus, Dieulafoy Lesions, Angiodysplasia, Gastric Antral Vascular Ectasia (GAVE) and Radiation Proctitis (RP). The device is to be used in adults only
{5}------------------------------------------------
6. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
Both the Aqua System and the HALO® predicate are comprised of a multiple use generator with optional footswitch and disposables. However, the Aqua System achieves its intended use by utilizing a slightly different technology from its primary predicate. While the HALO® is used to treat the esophagus by applying bipolar RF energy (creating heat) directly to the tissue, the Aqua System converts the bipolar RF energy to heated vapor which is then used to treat the tissue.
To bridge the technological gap between the two devices, comparative bench and animal testing were conducted. The results of the comparative testing demonstrate that the HALO" and the Aqua Medical RF Vapor System produce substantially equivalent results.
7. PERFORMANCE DATA
Below is a list of the tests that have been performed and successfully completed for the Aqua Medical RF Vapor System.
Biocompatibility:
The following biocompatibility tests were conducted:
- Cytotoxicity -
- -Hemolysis
- Systemic Toxicity -
- -Intracutaneous
- Sensitization -
- -Pyrogenicity
Electrical safety and electromagnetic compatibility (EMC):
The system was tested and found to comply with IEC 60601-1:2005/EN 60601-1:2006 Medical electrical equipment -Part 1: General requirements for basic safety and essential performance 3rd Ed. and IEC 60601-1-2:2007 Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests.
Software Verification and Validation Testing:
Software verification and validation testing were conducted, and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device is considered as a "major" level of concern.
Bench:
- -HW Verification Testing
- -System Validation Testing
- Distal Assembly Pull Test -
- Lesion Comparative testing -
{6}------------------------------------------------
Animal:
In order to demonstrate substantial equivalence and bridge the technological gap between the Aqua Medical RF Vapor System and its primary predicate, the company conducted an animal study including both acute and subacute animals. A total of six animals were utilized in the study; three animals were treated and evaluated acutely (Day = 0) and three animals were treated and evaluated subacutely (48 hours). Each animal's esophagus received multiple test and control treatments that were applied using two different treatment settings. The histopathological evaluation assessed acute thermal coagulation through the crosssectional layers of the esophagus. There were no pathological complications associated with the test or control treatments in any animal. Both the test and control treatments demonstrated the ability to create thermal coagulative tissue injury that penetrates in depth to the external muscularis of the esophagus in healthy swine. Neither test nor control treatments were associated with esophageal perforation, significant hemorrhage or significant clinical complication. The results of the study demonstrate that the Aqua Medical RF Vapor System and the HALO® are substantially equivalent.
Conclusion:
The Aqua Medical RF Vapor System has the same indications for use as the HALO® System and is substantially equivalent in technological and performance characteristics to the HALO® predicate. The results obtained from comparative testing further support our substantial equivalency claim.
Consequently, it is clear that the Aqua Medical RF Vapor System is as safe and effective as its predicate devices without raising any new safety and/or effectiveness concerns. Any differences have been addressed by extensive testing and validations and therefore negate any safety or effectiveness concerns.
§ 876.4300 Endoscopic electrosurgical unit and accessories.
(a)
Identification. An endoscopic electrosurgical unit and accessories is a device used to perform electrosurgical procedures through an endoscope. This generic type of device includes the electrosurgical generator, patient plate, electric biopsy forceps, electrode, flexible snare, electrosurgical alarm system, electrosurgical power supply unit, electrical clamp, self-opening rigid snare, flexible suction coagulator electrode, patient return wristlet, contact jelly, adaptor to the cord for transurethral surgical instruments, the electric cord for transurethral surgical instruments, and the transurethral desiccator.(b)
Classification. Class II (performance standards).